Founded in 2008, we are a biotechnology company focused on the in-house discovery and development of innovative therapies for chronic diseases with a particular emphasis on metabolic disorders. We aspire to bring innovative and effective treatment options to global patients with chronic diseases.
We focus on leveraging accumulated industry experience and established R&D capabilities for the discovery and development of differentiated therapeutics. We have cultivated a diverse pipeline of six product candidates to capture the significant market potential in prevalent chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM), obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC) and congenital hyperinsulinemia.
Management Team
MICHAEL MIN XU
The Chairman of the Board, an Executive Director and the General Manager
National talent
Over 30 years of clinical and research experience
National Distinguished Expert and project review expert for the State Administration of Foreign Experts Affairs
Clinical physician and protein structure expert
Ph.D. from Columbia University and M.D. from Xiangya School of Medicine